Blood Eosinophils and outcomes in severe hospitalized exacerbations of COPD

Blood Eosinophils and outcomes in severe hospitalized exacerbations of COPD

Background Patients with moderate exacerbations of COPD and the eosinophilic phenotype have better outcomes with prednisolone. Whether this outcome is similar in patients hospitalized with a severe exacerbation of COPD is unclear. We investigated the rate of recovery of eosinophilic and noneosinophi...

Descripció completa

Dades bibliogràfiques
Autors principals:	Bafadhel, M, Greening, NJ, Harvey-Dunstan, TC, Williams, JE, Morgan, MD, Brightling, CE, Hussain, SF, Pavord, ID, Singh, SJ, Steiner, MC
Format:	Journal article
Idioma:	English
Publicat:	Elsevier 2016

Ítems similars

Blood eosinophil guided prednisolone therapy for exacerbations of COPD: a further analysis.
per: Bafadhel, M, et al.
Publicat: (2014)

Inhaled glucocorticoids and COPD exacerbations.
per: Brightling, C, et al.
Publicat: (2015)

Characterisation of exacerbations of severe eosinophilic asthma (SEA) on mepolizumab compared to placebo
per: Shrimanker, R, et al.
Publicat: (2017)

COPD exacerbation severity and frequency is associated with impaired macrophage efferocytosis of eosinophils
per: Eltboli, O, et al.
Publicat: (2014)

Seasonality of eosinophilic and non-eosinophilic exacerbations of COPD
per: Barker, R, et al.
Publicat: (2017)

Characterising non-eosinophilic COPD
per: Hambleton, K, et al.
Publicat: (2015)

Blood eosinophils: a biomarker of COPD exacerbation reduction with inhaled corticosteroids
per: Siddiqui SH, et al.
Publicat: (2018-11-01)

Eosinophils in COPD: just another biomarker?
per: Bafadhel, M, et al.
Publicat: (2017)

Effect of levofloxacin on neutrophilic airway inflammation in stable COPD: a randomized, double-blind, placebo-controlled trial
per: Siva R, et al.
Publicat: (2014-02-01)

Airway bacteria measured by quantitative polymerase chain reaction and culture in patients with stable COPD: relationship with neutrophilic airway inflammation, exacerbation frequency, and lung function
per: Bafadhel M, et al.
Publicat: (2015-06-01)

Blood eosinophil count and exacerbation risk in patients with COPD.
per: Kerkhof, M, et al.
Publicat: (2017)

Eosinophilic airway inflammation and exacerbations of COPD: a randomised controlled trial.
per: Siva, R, et al.
Publicat: (2007)

Exacerbations of COPD
per: Pavord ID, et al.
Publicat: (2016-02-01)

Blood eosinophil count and GOLD stage predict response to maintenance azithromycin treatment in COPD patients with frequent exacerbations
per: Djamin, R, et al.
Publicat: (2019)

The acute wheezy adult with airways disease in the emergency department: a retrospective case-note review of exacerbations of COPD
per: Russell REK, et al.
Publicat: (2019-05-01)

Blood eosinophils: a biomarker of COPD exacerbation reduction with inhaled corticosteroids
per: Siddiqui, S, et al.
Publicat: (2018)

Mepolizumab for Eosinophilic Chronic Obstructive Pulmonary Disease (COPD): A Meta-Analysis of METREX and METREO Exacerbation Endpoints
per: Bafadhel, M, et al.
Publicat: (2018)

Shall we focus on the eosinophil to guide treatment with systemic corticosteroids during acute exacerbations of COPD?: PRO
per: Camp, J, et al.
Publicat: (2018)

Lung microbiome dynamics in COPD exacerbations
per: Wang, Z, et al.
Publicat: (2016)

Shall We Focus on the Eosinophil to Guide Treatment with Systemic Corticosteroids during Acute Exacerbations of COPD?: PRO
per: James Camp, et al.
Publicat: (2018-09-01)

Aspergillus fumigatus during stable state and exacerbations of COPD.
per: Bafadhel, M, et al.
Publicat: (2014)

The peripheral blood eosinophil count as a biomarker of eosinophilic airway inflammation in patients with asthma and COPD. Experience from a single centre
per: Shrimanker, R, et al.
Publicat: (2017)

Association between blood eosinophil count and risk of exacerbations in patients with COPD
per: Kerkhof, M, et al.
Publicat: (2017)

COPD in the time of COVID-19: an analysis of acute exacerbations and reported behavioural changes in patients with COPD
per: Hamish McAuley, et al.
Publicat: (2021-01-01)

Association Between Pathogens Detected Using Quantitative Polymerase Chain Reaction With Airway Inflammation in COPD at Stable State and Exacerbations.
per: Barker, B, et al.
Publicat: (2015)

Mepolizumab and exacerbations of refractory eosinophilic asthma.
per: Haldar, P, et al.
Publicat: (2009)

Copd in the ed: eosinophils, treatment and outcomes, data from the pre-award study
per: Russell, R, et al.
Publicat: (2016)

Mepolizumab for eosinophilic COPD
per: Sciurba, F, et al.
Publicat: (2018)

Clinical characterisation of exacerbations of severe eosinophilic asthma occurring on mepolizumab and placebo
per: Howell, I, et al.
Publicat: (2024)

Stability in eosinophil categorisation during subsequent severe exacerbations of COPD
per: Huib A M Kerstjens, et al.
Publicat: (2021-01-01)

Evaluation of exacerbations and blood eosinophils in UK and US COPD populations
per: Claus F. Vogelmeier, et al.
Publicat: (2019-08-01)

COPD exacerbations: transforming outcomes through research
per: Hurst, JR, et al.
Publicat: (2018)

Blood eosinophils to direct corticosteroid treatment of exacerbations of chronic obstructive pulmonary disease: a randomized placebo-controlled trial.
per: Bafadhel, M, et al.
Publicat: (2012)

Investigating blood eosinophil count thresholds in patients with COPD
per: Russell, R, et al.
Publicat: (2018)

The significance of eosinophilic inflammation in COPD
per: Cooper, C, et al.
Publicat: (2017)

Variability of blood eosinophil count and prognosis of COPD exacerbations
per: Sandra Martínez-Gestoso, et al.
Publicat: (2021-01-01)

Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial.
per: Green, R, et al.
Publicat: (2002)

Eosinophils in asthma and airway hyperresponsiveness.
per: Brightling, C, et al.
Publicat: (2004)

Building toolkits for COPD exacerbations: lessons from the past and present
per: Sapey, E, et al.
Publicat: (2019)

Is it time to give up on "self-management" of COPD exacerbations?
per: Ramakrishnan, S, et al.
Publicat: (2020)